Med Ed Report Briefs

The Coalition for Healthcare Communication and the Center for Medicine in the Public Interest released a white paper, Industry support for Continuing Education of Healthcare Professionals: An Evidence-Based Evaluation, arguing that industry support for CME is transparent, safeguarded against bias and essential to alleviating healthcare disparities and delivering better care to underserved populations.


Sen. Grassley (R-IA), perhaps the top CME conflict-of-interest hawk, will swap his ranking member position on the Finance Committee for that of the Judiciary Committee in 2011, according to reports, following the defection of the previous ranking member on Judiciary, Arlen Specter (D-PA), to the Democrats. That gives Grassley time to pass the Physician Payments Sunshine Act he coauthored with Sen. Kohl (D-WI). 


The AMA is partnering with Compuware subsidiary Covisint to develop a web portal that could include online CME. While nothing's set in stone, AMA officials said, the portal will feature "a variety of products, services and resources aimed at increasing medical practice efficiency and facilitating the adoption of health information technology."

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.